Primary debulking surgery of the upper abdomen and the diaphragm, with a plasma device surgery system, for advanced ovarian cancer

被引:10
|
作者
Vidal, Gloria Cordeiro [1 ]
Babin, Guillaume [1 ]
Querleu, Denis [1 ]
Guyon, Frederic [1 ]
机构
[1] Ctr Reg Lutte Canc, Inst Bergonie, 229 Cour, Bordeaux, France
关键词
Cytoreduction; Debulking; Ovarian cancer; Plasma; Diaphragmatic surgery;
D O I
10.1016/j.ygyno.2016.10.030
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
[Figure presented] Objective: Electrically neutral argon plasma (PlasmaJet™) technology is a surgical option that helps to get an aggressive cytoreduction in selected patients with ovarian cancer because it can be directly applied by the surgeon to treat the tissue surface [1,2]. Upper abdominal surgical procedures are an important part of the surgery in these patients [3], there is a 22% complications rate when they are performed [4]. We present a surgical approach to ovarian cancer debulking using PlasmaJet™. Methods: Case history and operative technique: 51 women supported for ovarian cancer Stage IIIC-IV were operated with systematic use of the PlasmaJet device at the Regional Institute Bergonié Cancer Center of Bordeaux, France between June 2012 and June 2014. 41.2% (n = 21) patients underwent a Primary Debulking Surgery (PDS) and 58.8% (n = 30) underwent an Interval Debulking Surgery. 78.4% (n = 40) of the 51 patients studied had a complete cytoreduction. We present the case of a woman diagnosed with a mucinous ovarian carcinoma FIGO stage IVA, who underwent a PDS. Complete cytoreduction to no macroscopic disease was achieved, this included diaphragmatic and abdominal peritoneal stripping. Results: No post-operative complications were found in this case. 15.7% (n = 8) of patients undergoing diaphragmatic stripping with the PlasmaJet required a pleural drain. It is a safe structured procedure, which could be performed to achieve optimal surgical results for patients with ovarian cancer. Conclusions: PlasmaJet™ helps the surgeon to perform a peritoneal stripping of the upper abdominal areas and appears to enable the surgeon to remove more disease without increased morbidity, pushing the cytoreduction/morbidity tradeoff. © 2016 Elsevier Inc.
引用
收藏
页码:223 / 224
页数:2
相关论文
共 50 条
  • [21] The impacts of neoadjuvant chemotherapy and of debulking surgery on survival from advanced ovarian cancer
    Rosen, Barry
    Laframboise, Stephane
    Ferguson, Sarah
    Dodge, Jason
    Bernardini, Marcus
    Murphy, Joan
    Segev, Yakir
    Sun, Ping
    Narod, Steven A.
    GYNECOLOGIC ONCOLOGY, 2014, 134 (03) : 462 - 467
  • [22] National Trends in Extended Procedures for Ovarian Cancer Debulking Surgery
    Jones, Nathaniel L.
    Chen, Ling
    Chatterjee, Sudeshna
    Tergas, Ana I.
    Burke, William M.
    Hou, June Y.
    Ananth, Cande V.
    Neugut, Alfred I.
    Hershman, Dawn L.
    Wright, Jason D.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 (01) : 19 - 25
  • [23] Primary or Interval Debulking Surgery in Advanced Ovarian Cancer: a Personalized Decision-a Literature Review
    Hudry, Delphine
    Becourt, Stephanie
    Scambia, Giovanni
    Fagotti, Anna
    CURRENT ONCOLOGY REPORTS, 2022, 24 (12) : 1661 - 1668
  • [24] Timing is everything: intraperitoneal chemotherapy after primary or interval debulking surgery for advanced ovarian cancer
    Lee, Jessica
    Curtin, John P.
    Muggia, Franco M.
    Pothuri, Bhavana
    Boyd, Leslie R.
    Blank, Stephanie V.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 82 (01) : 55 - 63
  • [25] Upper abdominal surgery in advanced and recurrent ovarian cancer: Role of diaphragmatic surgery
    Fanfani, Francesco
    Fagotti, Anna
    Gallotta, Valerio
    Ercoli, Alfredo
    Pacelli, Fabio
    Costantini, Barbara
    Vizzielli, Giuseppe
    Margariti, Pasquale Alessandro
    Garganese, Giorgia
    Scambia, Giovanni
    GYNECOLOGIC ONCOLOGY, 2010, 116 (03) : 497 - 501
  • [26] Timing is everything: intraperitoneal chemotherapy after primary or interval debulking surgery for advanced ovarian cancer
    Jessica Lee
    John P. Curtin
    Franco M. Muggia
    Bhavana Pothuri
    Leslie R. Boyd
    Stephanie V. Blank
    Cancer Chemotherapy and Pharmacology, 2018, 82 : 55 - 63
  • [27] Risk-prediction model of severe postoperative complications after primary debulking surgery for advanced ovarian cancer
    Kumar, Amanika
    Janco, Jo Marie
    Mariani, Andrea
    Bakkum-Gamez, Jamie N.
    Langstraat, Carrie L.
    Weaver, Amy L.
    McGree, Michaela E.
    Cliby, William A.
    GYNECOLOGIC ONCOLOGY, 2016, 140 (01) : 15 - 21
  • [28] Total rectosigmoidectomy versus partial rectal resection in primary debulking surgery for advanced ovarian cancer
    Plotti, F.
    Montera, R.
    Aloisi, A.
    Scaletta, G.
    Capriglione, S.
    Luvero, D.
    Nardone, C. De Cicco
    Basile, S.
    Panici, P. Benedetti
    Angioli, R.
    EJSO, 2016, 42 (03): : 383 - 390
  • [29] Debulking Surgery for Locally Advanced Ovarian Sarcomas
    Balescu, Irina
    Vilcu, Mihaela
    Bacalbasa, Nicolae
    Brasoveanu, Vladislav
    Brezean, Iulian
    Orban, Carmen
    PROCEEDINGS OF THE 4TH CONGRESS OF THE ROMANIAN SOCIETY FOR MINIMAL INVASIVE SURGERY IN GINECOLOGY / ANNUAL DAYS OF THE NATIONAL INSTITUTE FOR MOTHER AND CHILD HEALTH ALESSANDRESCU-RUSESCU, 2019, : 89 - 92
  • [30] Cytoreductive surgery in primary advanced epithelial ovarian cancer
    Luca Ansaloni
    Federico Coccolini
    Fausto Catena
    Luigi Frigerio
    Robert E Bristow
    World Journal of Obstetrics and Gynecology, 2013, (04) : 116 - 123